Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer by Audrey Brisebarre, Julien Ancel, Julien Ancel, Théophile Ponchel, Emma Loeffler, Adeline Germain, Véronique Dalstein, Véronique Dalstein, Valérian Dormoy, Anne Durlach, Anne Durlach, Gonzague Delepine, Gonzague Delepine, Gaëtan Deslée, Gaëtan Deslée, Myriam Polette, Myriam Polette, Béatrice Nawrocki-Raby

Get full text